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Abstract
This paper explores the question: Can interventions focusing on healing the gut microbiome of a
prediabetic patient prevent or delay the onset of type 2 diabetes? Diabetes is a major health
problem that is becoming the biggest epidemic of the 21st century. Efforts to derail the
progression of disrupted blood glucose metabolism are often futile leaving patients frustrated
with a lifelong burden of disease management. Recent studies suggest that collectively the gut
microbiome acts as an endocrine organ and that injury to this “organ” can lead to dysfunctional
glucose regulation. A comprehensive literature review revealed that further studies are needed to
explore alternative approaches to restoring normal glucose regulation. This proposed
quantitative, experimental study aims to explore the effectiveness of a weekly program focusing
on the establishment of a healthy gut microbiome to prevent the development of diabetes. The
proposed sample will be 100 prediabetic adult patients (ages 25-65) who will be randomly
divided into two groups: a treatment (Group A) and a control (Group B). All participants will
provide a baseline fasting blood glucose, A1C and a fecal sample before the start of the study.
Group A will attend an intensive educational program that consists of hour-long weekly
meetings for 12 weeks. Group A will attend weekly discussions of evidence-based research on
ways to promote a healthy gut microbiome. Activities that harm the gut thus promoting the
growth of pathogenic bacteria will also be discussed and discouraged. Group B, the control
group, will receive usual care which may or may not include recommendations from a physician
about exercise, diet and weight loss. At the end of the study, we will compare the two groups’
fasting blood glucose, A1C, and fecal microbiome composition.
Keywords: gut microbiota, gut microbiome, prediabetes, diabetes, glucose metabolism
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Gut Microbiota and the Development of Type 2 Diabetes
The Centers for Disease Control estimated in 2018 that 34.5% of the adult U.S.
population has prediabetes and 10.5% of the U.S. population has diabetes (2019). The CDC
cited a study by Gregg et al. in 2014 warning that two out of every five Americans are
expected to develop type 2 diabetes in their lifetime. A primary nursing role is to decrease the
prevalence of a disease such as type 2 diabetes by identifying the underlying cause and
addressing it. In an attempt to identify the underlying cause of chronic diseases ranging from
metabolic disease to gastrointestinal disorders to colorectal cancer, Hills et al. discuss how
recent research findings implicate the gut microbiome as the major influencer in the
development of these disorders (2019).
Humans have co-evolved with trillions of microbes, predominantly bacteria, living
symbiotically on and within various sites of the human body. New discoveries are being made
regarding the vital role the human microbiome plays in health and in disease. Microbiota is
defined as the microorganisms, including bacteria, fungi, and viruses, present in a defined
environment, such as a person’s oral cavity, genital organs, respiratory tract, skin, and
gastrointestinal system (Lloyd-Price et al., 2016). There are localized differences in the
microbiota of each person and microbiota from the skin will be radically different from gut
microbiota. It is estimated that there are roughly equal numbers of microbial cells inhabiting
the human body as there are human cells (Sender et al., 2016). The human microbiome is
defined as the collection of genomes, or DNA, from all the microorganisms in the
environment (Kho et al., 2018). Of all the human microbiomes, the gut microbiome houses the
most populous and diverse microbial communities. The gut microbiome, a topic of rapidly
growing research, has been referred to as a separate “organ” or the “second human genome”
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due to its large involvement in metabolic and immune activity (Ferranti et al., 2014).
Advances in technology, such as next-generation DNA sequencing (e.g., 16s rRNA
sequencing), have led to a surge in microbiome research as analysis has become faster and less
costly, thus more available. These advances have allowed researchers to identify the
microbiota present in the gut via stool sampling and to identify what physiological roles the
microbiota plays. While a diverse microbiota is considered healthier, the ideal composition for
a “healthy gut microbiota” has not yet been identified. However, a distinct microbial profile is
becoming apparent for individuals with metabolic disorders and glucose dysfunction. For
example, some researchers suggest that people with type 2 diabetes have a decreased number
of bacteria that produce short-chain fatty acids (e.g., acetate, propionate, and butyrate) (Lv et
al., 2018). Short-chain fatty acids are involved in mechanisms related to gut barrier function,
glucose homeostasis, immunomodulation, appetite regulation, and obesity (Chambers et al.,
2018). In summary, a closer look at the complex role of the gut microbiota is needed to
understand the development of glucose intolerance and to prevent the onset of type 2 diabetes.
Literature Review
The objective for this literature review is to explore various studies and see if their
findings can answer the following questions: What is the relationship between gut microbiota
and glucose metabolism; and can certain practices either harm gut microbiota populations or
promote a healthy gut microbiota to prevent the development of diabetes?
Search Strategy
The research literature was explored using multiple databases of the Dominican
University of California library, such as UpToDate and CINAHL, as well as Google Scholar.
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Various combinations of keywords were utilized in the search for research articles including the
following: gut microbiota, gut microbiome, prediabetes, prediabetic, type 2 diabetes, glucose
regulation, dysbiosis, artificial sweeteners, antibiotics, exercise, and fiber intake.
Six research articles were retrieved to create the literature review of this paper. These
articles explore how various activities influence the health of our gut microbiota for better or for
worse; either protecting us from developing diabetes or predisposing us to glucose metabolism
dysfunction.
Although there is extensive research on the gut microbiome and how it affects different
systems of our body, it was rather difficult finding primary quantitative research conducted on a
large sample of human subjects related specifically to diabetes and the gut microbiota. The
majority of research has been conducted on mice and the gut microbiota with a focus on
inflammatory bowel diseases. Analysis of the gut microbiome can be expensive and tricky to
manipulate due to its location and anaerobic microbiota. In fact, only in the last decade, as a
result of the widespread use of polymerase chain reaction and DNA sequencing, 16S rDNA
sequencing has allowed greater exploration of the role of the gut microbiome “including accurate
identification of bacterial isolates and the discovery of novel bacteria” (Woo et al., 2008). Many
studies included in this review utilized human fecal samples to explore the complex way that the
gut microbiota interacts with the body’s systems.
Road Map
The six articles discussed in this literature review are divided into three categories. The
first section is called “The Connection Between Gut Microbiome Compositions and Glucose
Metabolism.” It contains two articles that compare the gut microbiome composition of
individuals with normal blood glucose regulation with that of individuals with prediabetes or
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diabetes type 2. The comparison shows that a diverse gut microbiota is positively correlated with
normal glucose regulation. The second section is called “Activities that Result in Dysbiosis,” and
includes two research articles that explore practices that harm the gut microbiota, namely
antibiotic use and nonnutritive sweetener consumption. These activities ultimately increase the
risk of developing diabetes. The last section of the literature review is called “Activities that
Promote Good Gut Health” and it discusses two articles that focus on exercise and fiber intake
and their positive effects on gut microbiota. The objectives, methods, and findings of each article
are discussed in detail, along with the study’s strengths or limitations when appropriate. In
addition, each article prompts a brief discussion of relative nursing implications making the
research findings in these articles immensely valuable and practical. See Appendix A for a
summary of the literature review.
The Connection Between Gut Microbiome Compositions and Glucose Metabolism
The article Aberrant Intestinal Microbiota in Individuals with Prediabetes by Allin et al.
(2018) compared the gut microbiota of adults with prediabetes, obesity, insulin resistance,
dyslipidemia, and low-grade inflammation with individuals with normal blood glucose
regulation. The purpose of this study was to see if specific gut microbiota profiles are associated
with prediabetes and a range of clinical biomarkers of poor metabolic health (Allin e al., 2018).
Their inquiry was prompted by a former study called Disentangling Type 2 Diabetes and
Metformin Treatment Signatures in the Human Gut Microbiota by Forslund et al. (2017). In the
former study, associations between gut microbiota and type 2 diabetes were found, however, the
accuracy of those associations were called into question by Allin et al. because individuals with
diabetes 2 were taking metformin which actually alters gut microbiota. Therefore, Allin et al.’s
newer study includes individuals not currently treated with glucose-lowering drugs.
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This study compared the gut microbiota of 134 treatment-naïve Danish adults with
prediabetes (n=268) with 134 Danish age- and sex-matched adults with normal blood glucose.
Prediabetes is defined as a fasting plasma glucose of 6.1-7.0 mmol/l or HbA1c of 6.0-6.5%. The
design of this study is quantitative involving the analysis of fasting blood samples and the
measurement of plasma high-sensitivity C-reactive, HbA1c, plasma glucose, triacylglycerol, and
insulin levels. Fecal samples were collected by the participants at home and then they were
frozen. The fecal microbiota composition was later profiled by 16S rRNA sequencing. This
sequencing analysis “is a standard method in bacterial taxonomy and identification and is based
on the detection of sequence differences (polymorphisms) in the hypervariable regions of the
16S rRNA gene which is present in all bacteria” (Kim et al., 2011).
The results of the analyses were that individuals with prediabetes had a depletion of
several butyrate-producing bacteria compared to the individuals who had normal blood glucose
metabolism. Specifically, Allin et al. found a decreased abundance of the genus Clostridium and
the mucin-degrading bacterium A. muciniphila (2018). Butyrate is one of the three main shortchain fatty acids produced by the “friendly” bacteria in your gut. Multiple studies have found
that butyrate has anti-inflammatory and anti-cancer properties; it can improve glucose
metabolism and insulin sensitivity; and it can improve symptoms of ulcerative colitis and
Crohn's disease (McNabney & Henagan, 2017).
There are important nursing implications of the findings that increased species diversity
of the gut microbiota is associated with improved glucose regulation. These findings should
guide discussions on the prevention and treatment of prediabetes. Reversing the depletion as well
as preserving the populations of butyrate-producing bacteria in our gut could possibly delay the
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onset of glucose metabolism dysfunction and other related chronic conditions, including
metabolic syndrome.
The article Human Gut Microbiota Changes Reveal the Progression of Glucose
Intolerance by Zhang et al. (2013) examined the relationship of gut microbiota with the
development of type 2 diabetes. This quantitative, comparative study included 121 Chinese Han
subjects that were divided into three distinct groups of varying glucose tolerance: Normal
glucose tolerance (n=44), prediabetes (n=44), and newly diagnosed type 2 diabetes (n=13). Gut
microbiota were analyzed using 16S rDNA-based sequencing. Disruptions in the normal balance
of gut microbial populations were observed in the type 2 diabetes group. Metabolic parameters
(insulin measurements, A1c, lipid profiles, BP, CRP, WHR, etc.) and microbiota diversity were
compared and there was a significant association between the two. There was a higher
abundance of butyrate-producing bacteria (e.g. Akkermansia muciniphila, and Faecalibacterium
prausnitzii) in the normal glucose tolerance group than in the pre-diabetes group (Zhang et al.,
2013). In the type 2 diabetic group, the abundance of Bacteroides at the genus level was half that
of the normal glucose tolerance group and pre-diabetic group (Zhang et al., 2013). The study also
found that Verrucomicrobia had a significantly lower abundance in both the pre-diabetic and
type 2 diabetic groups (Zhang et al., 2013). Previous studies show that Verrucomicrobia may be
a potential marker of type 2 diabetes (Barlow et al., 2015).
The nursing implication for this research is that gut microbiota is altered in different
glucose intolerance status’ and therefore plays a role in the pathogenesis of diabetes. Further
studies are needed to explore this relationship so that we can prevent and treat glucose metabolic
dysfunction.
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Activities That Result in Dysbiosis
The article Gut Microbial Diversity in Antibiotic-Naïve Children After Systemic
Antibiotic Exposure: A Randomized Controlled Trial by Doan et al. (2017) evaluated the effects
of azithromycin on the gut microbiome diversity of children from an antibiotic-naïve community
in Niger. This article was found on Iceberg using the keywords: microbial diversity and
antibiotics. In this study, a population-based sample of 80 children (n=80), 1-60 months old,
from Niger, was randomized to receive a single dose or oral azithromycin or placebo (Doan et
al., 2017). The median age was 3 years old. After 5 days of treatment, 40 children were analyzed
from the antibiotic group and 40 from the placebo group. The goal of this study was to compare
the two groups’ fecal samples that were collected immediately before the administration of the
antibiotic and again 5 days after treatment. The samples were then profiled using 16S rRNA
sequencing to identify bacteria thus determine the samples’ composition and diversity. The
design of this study was quantitative. The authors utilized a population-based sample randomized
to receive the independent or the dependent variable. The results were statistically analyzed.
The outcome of the trial showed that “oral administration of azithromycin definitively
decreases the diversity of the gut microbiome of children in an antibiotic-naive community”
(Doan et al., 2017). The limitations of this study are the use of a pediatric population as the
sample and the rural location in Niger. The results may not be generalizable to all ages or
locations in the world. Furthermore, the second sample was collected after only 5 days showing
that the antibiotic caused a short-term decrease in diversity but not necessarily a long-term
change. A longitudinal study with a randomized control group of various ages and from various
cities in the United States over a longer period of time would prove useful for this topic.
Nevertheless, this study showed that even a single dose of antibiotics results in a reduction of
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bacterial diversity. Antibiotic use may disrupt normal glucose regulation. The number of people
diagnosed with diabetes continues to rise in the US. Therefore, healthcare providers need to
thoroughly analyze the risks and benefits associated with antibiotic use before carelessly
prescribing them to patients.
The article Are Nonnutritive Sweeteners Obesogenic? Associations Between Diet, Faecal
Microbiota, and Short-Chain Fatty Acids in Morbidly Obese by Farup et al. (2019) explored
changes in fecal microbiota and short-chain fatty acids of obese adults with a diet containing
nonnutritive sweeteners. NNSs are also known as artificial sweeteners.
This study included 14 men and 75 women from Norway with morbid obesity (defined as
BMI >40 or >35 kg/m2 with obesity-related comorbidity) and with an average BMI of 41.8
(Farup et al., 2019). The ages of the participants ranged from 18-65 with a mean age of 44.6. All
participants gave their medical history, had a physical exam, and had blood and fecal samples
collected. Their diet was assessed with a validated food frequency questionnaire. Participants had
an average intake of NNSs 7.5 units/day (SD 3.2; range 0–43). One unit of NNSs was equivalent
to 100 mL beverage with NNSs or 2 tablets/teaspoons of NNSs (Farup et al., 2019). The fecal
microbiota was assessed with a GA-map dysbiosis test. This advanced DNA testing targets
variable regions (V3 to V7) of the bacterial 16S rRNA gene in order to identify bacteria present
at different taxonomic levels (Farup et al., 2019). The short-chain fatty acids were assessed using
gas chromatography and flame ionization detection (Farup et al., 2019). This is a quantitative,
cross-sectional study of subjects who had been referred for evaluation for bariatric surgery in a
hospital in Norway.
The findings of this study were that fecal butyric acid was positively associated with the
intake of starch and negatively associated with the intake of nonnutritive sweeteners (partial
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correlation=0.264 and partial correlation=-0.274 respectively) (Farup et al., 2019). NNSs were
associated with changes in four out of 39 bacterial groups. Tests revealed reduced amounts of
Faecalibacterium prausnitzii, a butyrate-producing bacteria and reduced amounts of Bacteroides
fragilis, another bacterium that produces short-chain fatty acids. Farup et al. states that “lack of
butyric acid has weight-inducing effects and metabolic consequences that are unfavourable for
subjects with obesity” (2019). Tests also showed increased amounts of Ruminococcus gnavus,
which multiple studies have associated as a prevalent gut microbe in Crohn's disease (Henke et
al., 2019). There was also an increase in the Streptococcus species.
One strength of this study was that it took into account the following variables:
gender, age, height, weight, BMI, coffee (cups/day), smoking (daily, previously, and never),
previous and present diseases, and use of metformin and other drugs (yes/no). A limitation of
this study was that the specific types of NNSs were not discussed. Also, the tests measured fecal
amounts of short-chain fatty acids which could be construed as a poor estimate of short-chain
fatty acids in the colon. On the other hand, perhaps measuring fecal SCFA was sufficient
because quantities in feces depend on colonic production. Therefore, fecal measurements
indirectly reflect intestinal quantities and activity.
The nursing implication of this study is that consumption of nonnutritive sweeteners
should be discouraged, especially for individuals with prediabetes, type 2 diabetes, obesity or
metabolic syndrome. NNS consumption for reducing caloric intake or weight loss counteracts
the beneficial effects that butyric acid has on metabolism like reducing insulin resistance and
improving dyslipidemia. Nonnutritive sweeteners should be avoided because they decrease
beneficial gut microbiota populations and induce glucose intolerance.
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Activities That Promote Good Gut Health
The article Exercise and Associated Dietary Extremes Impact on Gut Microbial Diversity
by Clarke et al (2014) explored the positive impact that exercise and diet can have on gut
microbiota. It was difficult to find studies about exercise and changes on microbiota that
involved human participants, and not mice. Maybe it was difficult because there are many
confounding variables when measuring results from exercise.
This study included 86 total subjects from Cork County in Ireland. Of the 63 subjects,
forty (n=40) were male elite professional rugby players. The mean age was 29 (+ 4) years. The
remaining 46 subjects were healthy male controls with a mean age of 29 (+6) years. The two
groups of control were divided into a low BMI group < 25 (n=23) and a high BMI group >28
(n=23). Participants were excluded if they had a BMI between 25 and 28, antibiotic treatment
within the previous 2 months or were suffering from any acute or chronic cardiovascular, GI or
immunological condition (Clarke et al., 2014). All participants were interviewed by a
nutritionist and completed a detailed food frequency questionnaire that required diet recall from
the past 4 weeks. Fecal and blood samples were collected and DNA was extracted from fresh
stool samples which were stored on ice prior to use. The 40 athletes had to participate in a
rigorous training camp and the physical activity levels of both control groups were assessed. The
participants in the control groups were lean but considered sedentary. After four weeks, the fecal
samples were examined using 16s rRNA sequencing. This was a quantitative, comparative study.
The results revealed that the athlete microbiota had a greater alpha diversity and a higher
relative abundance of 40 different bacterial taxa compared to the microbiota of both sedentary
controls (Clarke et al., 2014). Also, the alpha diversity of the two control groups did not differ
significantly from each other. In other words, high or low BMI did not have an effect on
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microbiota diversity. In terms of diet, the athlete group consumed “significantly higher quantities
of calories, protein, fat, carbohydrates, sugar and saturated fat per day than either of the control
groups and consumed significantly higher quantities of fibre, monounsaturated fat and
polyunsaturated fat than the high BMI control group” (Clarke et al., 2014). In summary, the
results of this study suggest that diet and exercise are contributors to diversity in the gut.
The nursing implication for this study is that exercise, coupled with healthy eating habits,
can improve the diversity of the gut. Patients are frequently told that caloric energy spent should
equal caloric consumption in a dry, mathematical type equation. The interaction of food, exercise
and gut microbiota, which is considered a type of metabolic organ, is much more complex than a
simple equation of counting calories in versus calories out. Teaching patients about the changes
that occur at the microscopic level due to exercise and diet could guide interventions that focus
more on microbiome health and less on strict calorie counting.
The article Gut Bacteria Selectively Promoted by Dietary Fibers Alleviate Type 2
Diabetes by Zhao et al. (2018) aimed to show that certain short-chain fatty acid-producing
bacterial strains are promoted by dietary fibers which results in better hemoglobin A1c levels.
This quantitative, randomized clinical study included specifically designed diets equal in energy,
and fecal analysis using shotgun metagenomics to show that fiber increased the diversity and
abundance of SCFA producers which in turn led to improved hemoglobin A1c levels (Zhao et
al., 2018).
Patients with clinically diagnosed type 2 diabetes were randomized. The control group (U
group; n = 16 patients) received the standard care according to 2013 Chinese Diabetes guidelines
for T2DM, which includes patient education and diet recommendations (Zhao et al., 2018). The
treatment group (W group; n = 27 patients) received a high-fiber diet composed of whole grains,
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traditional Chinese medicinal foods, and prebiotics (also called the WTP diet) (Zhao et al., 2018)
Both groups received an anti-diabetic prescription medication similar to metformin, called
acarbose as the standardized medication. The daily energy and macronutrient intake were similar
for both groups but the authors wanted the treatment group (W) to have a higher intake of dietary
fibers to see if it would improve the HbA1c of the subjects. The subjects had their baseline
hemoglobin A1c levels, fasting blood glucose levels, postprandial glucose levels, body weight
and blood lipid profiles taken before the study (Pre; day 0) and after the treatment (Post; day 84).
The clinical data showed that although both groups showed improved glycemic control, “the
proportion of the participants who achieved adequate glycemic control (HbA1c < 7%) at the end
of the intervention was also significantly higher in the W group (89% versus 50% in the U
group)” (Zhao et al., 2018). The W group also showed a greater reduction in body weight and
better blood lipid profiles than the U group. These findings indicate that increased availability of
nondigestible, fermentable carbohydrates is “sufficient to induce clinically relevant metabolic
improvements in patients with T2DM” (Zhao et al., 2018).
To determine causality between the gut microbiota and fiber-induced improvement of
host glycemic control, two fecal samples were collected from the same participant; one from preintervention and one post-intervention. The gut microbiota from each of the fecal samples was
then transplanted into germ-free mice (Zhao et al., 2018). Mice that received post-intervention
microbiota from the W group had the lowest fasting and postprandial blood glucose levels
among all mice which reflected the better metabolic outcomes in participants of the W group
than in those of the U group (Zhao et al., 2018). The transferable effects of the treatments via
microbial transplantation provided evidence that the gut microbiota can improve glucose
regulation in patients with T2DM when gut microbiota is provided fiber to “eat.”
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The nursing implication for these findings is that nurses should encourage patients with
dysfunctional glucose regulation to eat fiber. Feeding fiber to gut microbiota helps them flourish.
When certain microbes ferment fiber they produce short-chain fatty acids that act as important
metabolites for their human host. For example, short-chain fatty acids play a role in glucose
regulation and lipid metabolism, and possibly reduce the risk of developing GI disorders like
Crohn’s, anti-inflammatory diseases, cancer, and cardiovascular disease (Tungland, 2018).
Repopulating the gut with SCFA-producing bacteria may be the best way to treat various
dysbiosis-related diseases, including diabetes, or at least an effective way to prevent the disease’s
progression.
Discussion
In summary, the aim of this literature review was to explore the connection between the
gut microbiome and altered glucose metabolism. This review included six articles in total. Two
articles identified the existence of a relationship between the gut microbiome and glucose
metabolism dysfunction. Two articles illustrated that the gut microbiome can be negatively
impacted by antibiotic use and artificial sweetener consumption. The last two articles illustrated
that exercise and fiber consumption can promote healthy and diverse gut microbiota.
One strength of some of the studies was that they collected objective data and used
advanced technology, such as 16s rRNA sequencing, for their analysis. A limitation was that a
couple studies population samples were relatively small or from other parts of the world. Also,
some of the findings may not be generalizable conclusions because of difficulty in controlling
relevant confounding variables. Restricting patients to identical diets may be one way to control
the confounding variables of diet assessment. Further studies on this topic could include bigger
sample sizes and longitudinal studies. Nevertheless, the findings of this literature review are
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definitely eye-opening and worthy of guiding practice in the prevention and treatment of glucose
metabolism dysfunction.
Proposal for Further Study
It is clear that further studies are needed to explore how healthy gut microbiota promotion
leads to better outcomes for people with prediabetes. In my literature review, I did not encounter
quantitative research comparing a prediabetic group receiving conventional pharmacological
treatment with a prediabetic group receiving educational intervention regarding practices that
promote healthy gut flora. Traditional approaches to treat people with prediabetes are failing.
According to Anthony Komaroff, MD, at Harvard Medical School, 25% of people with
prediabetes will develop full-blown diabetes within 3-5 years and the percentage is significantly
larger over the long term (2013). This prognosis could be due to a one-size-fits-all protocol
treatment that focuses on symptoms of the disease instead of the cause. According to Medscape,
people newly diagnosed with insulin deficiency or resistance are usually advised to reduce
weight by 5-10%, exercise 30-60 minutes at least 5 times per week, eat or not eat certain foods,
and take medication (2020). Many of the medications prescribed to patients with prediabetes are
the same as those given to patients with type 2 diabetes. These medications treat the symptoms
of dysbiosis such as elevated glucose levels, hyperlipidemia, and high blood pressure. These
medications do not treat the cause of dysbiosis, so people are left with a lifelong list of
prescriptions that carry with them side effects that often lead to nonadherence. Can patient
education and further research on the relationship between gut microbiota health and chronic
diseases like diabetes lead to better outcomes for patients with prediabetes?
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Theoretical Framework
The nursing theory of Fay Abdellah serves as the framework for this study. According to
the National Women’s Hall of Fame website, Dr. Faye Abdellah was an educator, and the first
nurse and woman to serve as Deputy Surgeon General (1981-1989) (2020). She helped
transform the practice of nursing from “a disease-centered to a patient-centered approach,” and
raised the standards of nursing practice “by introducing scientific research into nursing and
patient care” (National Women’s Hall of Fame website, n.d.). The National Library of Medicine
states that Dr. Abdellah advocated for nursing education to be based on science and research, for
nurses to teach self-care to patients, and for an interdisciplinary approach to nursing care (2020).
Faye Abdellah’s Twenty-One Nursing Problems Theory embodies the theoretical
framework for this study. These twenty-one nursing problems are broken down into ten steps
used to identify the patient’s problems, and eleven skills used to develop a nursing care plan. The
framework focuses on individualizing patient care, problem-solving, and patient-centered
therapeutic plans. Skills of communication and education of patients and families are just two of
her 11 skills listed (Abdellah, 1968). These are important aspects of this proposed study. For
example, traditionally, the prediabetic patient is instructed to lose weight by avoiding sugar and
excess calories. This explanation alone would result in patients reaching for foods that are low
calorie or sugar-free, but that may also contain highly processed ingredients that wreak havoc on
gut microbiota. The hypothesis of this study is that patient education will lead to a better
understanding of the disease process which will ultimately guide patient behaviors and improve
glucose metabolism.
Another step Faye Abdellah used to identify the patient’s problem was “explore the
patient and his or her family’s reactions to the therapeutic plan and involve them in the plan”
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(Abdellah, 1968). The success of a treatment plan depends on patient adherence. If the patient is
actively involved in the formulation of the treatment plan, the patient will take more ownership
of the implementation. Although diabetes causes common signs and symptoms in patients, a onesize-fits-all approach is not effective in treatment. The patient, and not the disease, will guide the
details of a treatment plan in this study. Focusing on patient education and care plan
individualization is paramount to this study and thus aligns well with Faye Abdellah’s nursing
theory.
Primary Research Aims
•

This proposed quantitative, experimental study aims to compare fasting blood glucose
and A1c, and microbial composition between two groups of prediabetic patients, one
control group receiving usual care and an intervention group receiving weekly
educational meetings and guidance on how to re-establish a healthy and diverse gut
microbiome

•

The hypothesis of this study is that the prediabetic group who participate in the
educational program will have better markers of blood glucose control and an improved
microbiota composition by the end of the study compared to the prediabetic group who
only receive usual care

Ethical Considerations
The participants will be given a letter with the purpose of the study and what
participation entails. Participants will be informed that they can drop out at any point in the study
if they wish. Their participation is completely voluntary. The participants will not be
compensated for their participation, but could hypothetically improve their health. The letter will
state that there will not be any economic risk, psychological risk, nor physical risk as long as
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moderate exercise is not contraindicated. The only physical discomfort will be from having
blood samples collected three separate times. Participants’ privacy and confidentiality will be
honored throughout the process. Data collected will be used for research purposes only and
stored in a password-protected computer to maintain strict confidentiality. The proposed study
will be approved by Kaiser Permanente San Rafael’s Internal Review Board.
Research Method
This proposed quantitative study will compare fasting blood glucose, A1C, and
microbiota composition from two groups of prediabetic participants before the study begins,
after the treatment, and 24 weeks after the beginning of the study. The population sample will
include men and women from 25 to 65 years old who meet the criteria of prediabetic and who
are patients at Kaiser San Rafael. The proposed sample size will consist of 100 prediabetic adults
who will be randomly divided into two groups. The treatment group, Group A, will consist of 50
patients who will participate in an intensive educational program of hour-long weekly meetings
for 12 consecutive weeks. The weekly discussions will cover evidenced-based research and
literature on ways to promote a healthy gut microbiome as a means to obtain normal blood
glucose regulation. Activities that harm the gut and diminish microbe diversity, such as taking
antibiotics and consuming artificial sugar sweeteners, will also be discussed. Discussions will
explain exactly how certain activities, like eating fiber and exercising, promote a healthy
microbiome. The control, Group B, will consist of fifty patients who will not receive treatment in
the form of an educational program. The only possible intervention Group B will receive are the
standard verbal recommendations provided by their physicians. All participants will provide a
baseline fasting blood glucose, HbA1C, and a fecal sample before the start of the study, after 12
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weeks when the study concludes, and again at 24 weeks from the start of the study to test for
long term effects.
Recruitment for this study will involve identifying Kaiser patients that meet inclusion
criteria. Inclusion criteria include being prediabetic as defined as having a fasting blood glucose
between 100 mg/dl and 126 mg/dl and a hemoglobin A1c from 5.7% to 6.4% (Dansinger, 2019).
Exclusion criteria include antibiotic treatment within the past two months, current metformin or
other antihyperglycemic therapy, or suffering from any severe cardiovascular, gastrointestinal or
immunological condition. After identifying eligible patients, researchers will contact patients
who will be given a brief description of the study, expected requirements for participation, and
hypothesized outcomes. Patients will then be asked if they would like to volunteer. Patients will
be informed that in the event they are randomly chosen for the control group, they will be able to
attend an educational program at the end of the study if they chose. In this way, a service that is
deemed beneficial is being offered to both groups but just not simultaneously. Participants will
be reminded that even after providing informed consent, they can stop participating at any time.
For this quantitative, experimental study, a t-test will determine if there is a significant
difference between the two groups’ fasting blood glucose and HbA1c pre-treatment and posttreatment. 16s rRNA gene sequencing will be used to measure the microbial diversity and
composition of the provided fecal samples from the two groups at the three different points in
time. Gas chromatography and flame ionization detection will specifically measure the quantity
of short-chain fatty acids, such as butyrate, in the stool samples as this is the byproduct of certain
beneficial gut microbes. These beneficial species assist in gut homeostasis by their
immunomodulatory functions as well as by maintaining metabolism such as blood glucose
regulation (Nepelska et al., 2012).
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Conclusion
After a thorough literature review of research, it is evident that there is a strong
relationship between the health of the gut microbiome and human health. Gut dysbiosis and its
role in the pathogenesis of disease needs to be further explored as it has been noted in patients
with glucose metabolic dysfunction. More research is also needed on the beneficial role of the
short-chain fatty acids produced by bacteria in the gut. Technological advances have made
identification of gut microbial taxa possible, and the association between certain taxa and
systemic inflammatory diseases is becoming evident. In the future, the presence of certain
microbial populations or the absence of others might be used as biomarkers for diagnosing
inflammatory diseases such as diabetes, ulcerative colitis, Crohn’s disease, multiple sclerosis,
rheumatoid arthritis, psoriasis and even cardiovascular disease (Barnes et al., 2016). To date, the
majority of data analysis of microbial communities’ role in disease has been collected from
research on mice. The number of studies on human participants is growing at the same time as
the prevalence of inflammatory diseases is growing, and scientists are desperately searching for
their etiologies. The effectiveness of fecal microbiota transplantation in the treatment of
Clostridium difficile infection has made manipulation of the gut microbiota even more attractive
as a treatment option for diabetes and idiopathic conditions (Borody, 2011). In the future, fecal
samples may be collected as routinely as blood samples to diagnose and treat inflammatory
conditions.
This proposed research study with prediabetic patients will advance the nursing
profession by exploring alternative methods to correct dysfunctional glucose metabolism. This
proposed study uses Faye Abdellah’s theory of nursing care by focusing on treatment that is
patient-centered instead of disease-centered. The twelve-week educational program will allow
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patients to understand the “why” behind specific recommendations which will lead to better
treatment adherence and in turn better glucose regulation. Patients will understand that
maintaining diverse and rich gut microbiota reduces inflammation and promotes healthy glucose
metabolism. This study shifts the focus of nursing care from symptom management to patient
education providing an opportunity for patients to take part in the prevention of their disease
development. Patients will avoid a life sentence of pharmacological therapy, hospital visits, and
potential complications such as amputations, end-stage kidney disease and dialysis treatment. In
the future, more research is needed to explore the “neglected endocrine organ,” known as our gut
microbiota (Clarke et al., 2014). Let’s listen to our gut.
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